Physician profile
Matthew T Ritter
NPI 1528095270
$2,022.81
in general payments reported to CMS, 2019-2025
22 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.76 · 2020: $63.63 · 2021: $156 · 2022: $191 · 2023: $194 · 2024: $962 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $306.60 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $292.08 | 2022-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Abbvie INC. | $201.24 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Visioneering Technologies, INC. | $193.24 | 2024 | |
| Novartis Pharmaceuticals Corporation | $154.90 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $143.40 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Glaukos Corporation | $123.52 | 2024 | |
| Biotissue Holdings INC. | $108.46 | 2022-2025 | |
| Harrow Eye, LLC | $105.77 | 2024 | Vevye |
| Johnson & Johnson Vision Care, INC. | $92.67 | 2020-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.30 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $34.26 | 2022-2023 | Cequa |
| Allergan, INC. | $33.04 | 2019-2022 | |
| Coopervision INC. | $32.73 | 2020-2021 | |
| Lombart Brothers, INC. | $30.27 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.11 | 2021 | |
| Thea Pharma INC. | $16.99 | 2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $16.20 | 2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $15.41 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.85 | 2022 | |
| Shire North American Group INC | $13.84 | 2019 | |
| Optos, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ritter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.